<?xml version="1.0" encoding="UTF-8"?>
<p>Palivizumab is a humanized monoclonal antibody found to have strong RSV-neutralizing capability against a range of RSV strains. The palivizumab 24-aa epitope structure on the RSV F protein is well characterized (
 <xref rid="ref125" ref-type="bibr">Schickli et al., 2015</xref>). The drug has been shown to be effective in preventing RSV-related hospitalizations in children (
 <xref rid="ref52" ref-type="bibr">Frogel et al., 2008</xref>). Although the efficacy of this antiviral against RSV infection is proven, due to the considerable cost of palivizumab, the usage is limited to the high-risk populations (
 <xref rid="ref127" ref-type="bibr">Shahabi et al., 2017</xref>) including infants and young children (
 <xref rid="ref27" ref-type="bibr">Centers for Disease Control and Prevention, 2018b</xref>).
</p>
